{
    "2018-04-11": [
        [
            {
                "time": "",
                "original_text": "强于大市评级医药生物行业专题研究：从样本医院数据看药品结构调整：36个谈判品种2017Q4放量增长 刚需药品龙头增速稳健",
                "features": {
                    "keywords": [
                        "医药生物",
                        "药品结构调整",
                        "谈判品种",
                        "2017Q4",
                        "放量增长",
                        "刚需药品",
                        "龙头"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业2017年业绩双降",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "2017年",
                        "业绩双降"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}